Clinical Trials Logo

Clinical Trial Summary

Chronic thromboembolic Pulmonary hypertension(CTEPH) is characterized by obstruction of the pulmonary vasculature, leading to increased pulmonary vascular resistance, progressive pulmonary hypertension (PH) and right ventricular failure- most common cause of death for patients with PH. Riociguat, (ADEMPAS) is a member of a new class of drug recently approved in Canada for the treatment of CTEPH.

This pilot study is designed to assess if at least 24 weeks of treatment with riociguat will show changes in glucose metabolism and improved resting myocardial blood flow using positron emission tomography ( PET ) imaging to measure myocardial function. The response between both treatment naive patients as well as patients on maximally tolerated dose of riociguat with tratment duration of at least 3 months will be included.


Clinical Trial Description

It remains unclear as to why certain patients with PH develop right heart failure. Several lines of evidence suggests alterations in right ventricular (RV) function may be precipitated by RV ischemia. This ischemia results from both decreased right coronary artery perfusion pressure and from arteriolar- capillary rarefaction. It has been proposed that this contributes to insufficient oxygen delivery needed to support the increase RV demand in right heart failure (RHF), this stimulating glycolytic shift. However, this glycolysis is insufficient to compensate for suppression of glucose oxidation in severe right ventricular hypertrophy (RVH), resulting in a state of RV hibernation and progressive RHF.

This study is designed to assess if 24 weeks of treatment with riociguat will be associated with changes in glucose metabolism and improved RV blood flow using N-13-ammonia (NH3) to measure myocardial perfusion.

We will assess the response in both treatment naive patients as well as patients who have been titrated to maximally tolerated doses of riociguat with total treatment duration of at least 3 months.

The assessment of quantitative myocardial blood flow will be combined with an advanced 3 dimensional echocardiographic assessment of RV volume and function and with cardiac magnetic resonance (MR). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02094001
Study type Interventional
Source Ottawa Heart Institute Research Corporation
Contact
Status Completed
Phase Phase 2
Start date May 2014
Completion date June 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06003244 - High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT) N/A
Active, not recruiting NCT06092424 - High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA) N/A
Active, not recruiting NCT06072417 - HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level) N/A
Terminated NCT01953965 - Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI. Phase 2
Recruiting NCT02061787 - the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension
Not yet recruiting NCT03102294 - Inspiratory Muscle Training in Chronic Thromboembolic Pulmonary Hypertension N/A
Recruiting NCT04071327 - Pulmonary Hypertension Association Registry
Completed NCT00313222 - Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension Phase 3
Recruiting NCT05311072 - Change-a Multi-center Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Database in China
Recruiting NCT05340023 - Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension
Enrolling by invitation NCT05568927 - Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism
Completed NCT03786367 - Dyspnea in Chronic Thromboembolic Pulmonary Hypertension
Recruiting NCT04081012 - N-acetyl Cysteine in Post-reperfusion Pulmonary Injury in Chronic Thromboembolic Pulmonary Hypertension. N/A
Not yet recruiting NCT06384534 - Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD) N/A
Withdrawn NCT05693779 - Exercise Therapy After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension N/A
Not yet recruiting NCT02426203 - 3D Echocardiographic Assessment of RV Function in Patients Undergoing Pulmonary Endarterectomy N/A
Enrolling by invitation NCT03388476 - Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension
Recruiting NCT04206852 - Safety and Efficacy of Balloon Pulmonary Angioplasty in China
Completed NCT02111980 - RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators N/A
Enrolling by invitation NCT05618093 - Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH N/A